|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
NZ567324A
(en)
*
|
2003-02-01 |
2009-08-28 |
Wyeth Corp |
Active immunization to generate antibodies to soluble A-beta
|
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
|
AU2005294131A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Wyeth |
Methods and compositions for improving recombinant protein production
|
|
US7625560B2
(en)
|
2004-12-15 |
2009-12-01 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
EP1838348B1
(en)
|
2004-12-15 |
2013-06-26 |
Janssen Alzheimer Immunotherapy |
Humanized amyloid beta antibodies for use in improving cognition
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
ZA200710330B
(en)
*
|
2005-06-17 |
2009-12-30 |
Wyeth Corp |
Methods of purifying FC region containing proteins
|
|
TW200806317A
(en)
*
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
TW200806315A
(en)
*
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
CL2007003583A1
(es)
*
|
2006-12-11 |
2008-07-18 |
Hoffmann La Roche |
Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
|
|
TW200844110A
(en)
|
2007-01-11 |
2008-11-16 |
Univ Marburg Philipps |
Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
|
|
RU2476442C2
(ru)
|
2007-03-29 |
2013-02-27 |
Эббот Лэборетриз |
Кристаллические антитела против il-12 человека
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
DK2182983T3
(da)
|
2007-07-27 |
2014-07-14 |
Janssen Alzheimer Immunotherap |
Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
|
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
US8796206B2
(en)
|
2007-11-15 |
2014-08-05 |
Amgen Inc. |
Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
|
|
US8420081B2
(en)
*
|
2007-11-30 |
2013-04-16 |
Abbvie, Inc. |
Antibody formulations and methods of making same
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
PE20091174A1
(es)
*
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
WO2009113083A1
(en)
|
2008-03-14 |
2009-09-17 |
Biocon Limited |
A monoclonal antibody and a method thereof
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
US10005830B2
(en)
*
|
2009-03-05 |
2018-06-26 |
Ablynx N.V. |
Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
CA2765220A1
(en)
*
|
2009-07-14 |
2011-01-20 |
Biogen Idec Ma Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
|
US9345661B2
(en)
*
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
EP2519539A4
(en)
*
|
2009-12-28 |
2013-11-13 |
Ligocyte Pharmaceuticals Inc |
METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
|
|
BR112012013148A2
(pt)
*
|
2009-12-29 |
2017-03-21 |
F Hoffmann - La Roche Ag |
formulação farmacêutica e uso
|
|
PT3345615T
(pt)
|
2010-03-01 |
2020-01-17 |
Bayer Healthcare Llc |
Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
|
|
ES2757591T3
(es)
|
2010-03-31 |
2020-04-29 |
Stabilitech Biopharma Ltd |
Estabilización de partículas virales
|
|
WO2011121301A1
(en)
|
2010-03-31 |
2011-10-06 |
Stabilitech Ltd |
Excipients for stabilising viral particles, polypeptides or biological material
|
|
CA2795050C
(en)
|
2010-03-31 |
2018-05-22 |
Stabilitech Ltd. |
Method for preserving alum adjuvants and alum-adjuvanted vaccines
|
|
PL2575870T3
(pl)
|
2010-06-04 |
2017-05-31 |
Wyeth Llc |
Preparaty szczepionek
|
|
US8821865B2
(en)
|
2010-11-11 |
2014-09-02 |
Abbvie Biotechnology Ltd. |
High concentration anti-TNFα antibody liquid formulations
|
|
EP2471554A1
(en)
*
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
|
EP2500035A1
(en)
*
|
2011-03-15 |
2012-09-19 |
Icon Genetics GmbH |
Pharmaceutical formulation containing immunglobulin
|
|
PT2691112T
(pt)
|
2011-03-31 |
2018-07-10 |
Merck Sharp & Dohme |
Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
|
|
GB201117233D0
(en)
|
2011-10-05 |
2011-11-16 |
Stabilitech Ltd |
Stabilisation of polypeptides
|
|
JP2015526409A
(ja)
*
|
2012-07-03 |
2015-09-10 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Ｃ−末端及び中心エピトープａ−ベータ抗体
|
|
US9592297B2
(en)
*
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
EP3024485B1
(en)
|
2013-07-23 |
2020-11-18 |
Biocon Limited |
Use of a cd6 binding partner and method based thereon
|
|
IL312865B2
(en)
*
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
GB201320660D0
(en)
*
|
2013-11-22 |
2014-01-08 |
Qualasept Ltd |
Method
|
|
GB201406569D0
(en)
|
2014-04-11 |
2014-05-28 |
Stabilitech Ltd |
Vaccine compositions
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
HUE057952T2
(hu)
|
2015-06-24 |
2022-06-28 |
Hoffmann La Roche |
Anti-transzferrin receptor antitestek testreszabott affinitással
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
TWI873952B
(zh)
|
2015-10-02 |
2025-02-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
|
GB201604124D0
(en)
*
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
CN107446044B
(zh)
*
|
2016-05-30 |
2021-04-30 |
越海百奥药业(绍兴)有限公司 |
一种纯化抗体的方法及所用缓冲液
|
|
JP7386080B2
(ja)
*
|
2016-08-02 |
2023-11-24 |
アンバー アイピー リミテッド |
安定なイブプロフェン注射製剤用組成物
|
|
ES2991182T3
(es)
|
2016-10-21 |
2024-12-02 |
Biocon Ltd |
Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
|
|
GB201703063D0
(en)
|
2017-02-24 |
2017-04-12 |
Arecor Ltd |
Stabilized antibody protein solutions
|
|
US11608357B2
(en)
|
2018-08-28 |
2023-03-21 |
Arecor Limited |
Stabilized antibody protein solutions
|
|
EP3372242A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
EP3372241A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
JP7382232B2
(ja)
|
2017-05-02 |
2023-11-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
|
|
GB2562241B
(en)
|
2017-05-08 |
2022-04-06 |
Stabilitech Biopharma Ltd |
Vaccine compositions
|
|
CN118370815A
(zh)
*
|
2017-08-22 |
2024-07-23 |
渤健马萨诸塞州股份有限公司 |
含有抗β淀粉样蛋白抗体的药物组合物
|
|
CA3081144A1
(en)
|
2017-12-08 |
2019-06-13 |
Argenx Bvba |
Use of fcrn antagonists for treatment of generalized myasthenia gravis
|
|
US12202900B2
(en)
*
|
2018-06-08 |
2025-01-21 |
argenx BV |
Compositions and methods for treating immune thrombocytopenia
|
|
WO2020081408A1
(en)
|
2018-10-18 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
MX2021004928A
(es)
|
2018-10-31 |
2021-06-08 |
Merck Sharp & Dohme Llc |
Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
|
|
EP3876990A4
(en)
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
GB201906917D0
(en)
*
|
2019-05-16 |
2019-07-03 |
Intract Pharma Ltd |
Novel compositions
|
|
JP2023509195A
(ja)
|
2020-01-08 |
2023-03-07 |
アルジェニクス ビーブイ |
天疱瘡症を治療する方法
|
|
CN114404575A
(zh)
*
|
2020-12-07 |
2022-04-29 |
苏州智核生物医药科技有限公司 |
一种重组人促甲状腺素注射液
|
|
CN119698429A
(zh)
|
2022-06-15 |
2025-03-25 |
阿根思有限公司 |
Fcrn结合分子及使用方法
|